Fairvalue-Calculator Fairvalue-Calculator
EN DE

Youcare Pharmaceutical Group (688658) Fair Value & Analysis

Healthcare · CN · Market cap 6.1B CNY

Price¥13.08
Fair Value¥6.66
Upside-49.1%
Quality92/100
Evidence: Medium Range ¥4.85 – ¥8.47

Analysis

Youcare Pharmaceutical Group (688658) currently trades at ¥13.08, while our model-based Fair Value estimate is ¥6.66 — implying the stock looks roughly 49.1% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Youcare Pharmaceutical Group Co., Ltd. engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It offers drugs in various forms, such as injection, lyophilized powder injection, pills, tablets, capsules, ointments, creams, granules, etc. The company provides drugs in various categories, including covering cardio-cerebrovascular, antivirals, central nervous system medication, turbidity and lipid-lowering, gastrointestinal system, anti-infection, endocrinology anti-tumour and other therapeutic areas. It also offers raw materials, pharmaceutical excipients, and formulations. Youcare Pharmaceutical Group Co., Ltd. was founded in 1988 and is headquartered in Beijing, China.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.